Cohance Lifesciences credit rating upgraded to AA- after strategic moves

Cohance Lifesciences Limited (formerly Suven Pharmaceuticals Limited) announced on August 27, 2025, that CRISIL Ratings has upgraded its long-term bank facility rating to 'CRISIL AA-/Positive' from 'Crisil A+'. Its short-term rating was reaffirmed at 'CRISIL A1+'. This upgrade, effective August 26, 2025, reflects the completion of the amalgamation process and recent acquisitions, which have significantly strengthened the company's business and financial risk profiles. Operating income is projected to more than double in fiscal 2026.

Concurrently, Cohance Lifesciences disclosed the sale of 600,000 shares by managing director Dr. V Prasada Raju on August 26, 2025, for Rs. 52.82 Crores. This transaction was undertaken to repay a loan for exercising stock options and to discharge personal financial obligations.

The company also announced an upcoming analyst/institutional investor meeting with Elara Ashwamedh Conference in Mumbai on September 4, 2025. This group/one-on-one meeting will not include any unpublished price-sensitive information.